Rychnov Nad Kneznou

• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 5 Agitation Associated with Alzheimer’s Disease
• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521711-39-00 5 2026-05-17 Lewy body Dementia psychosis (LBDP)
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting
  2025-520746-30-00 5 2025-11-18 Mild to moderate Alzheimer’s Disease
• A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting
  2024-512904-21-00 4 2025-12-10 Migraine
• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521710-25-00 4 2025-12-04 Lewy Body Dementia Psychosis (LBDP)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520612-34-00 5 2025-11-28 Agitation Associated with Alzheimer’s Disease
• A Phase 2a, Multi-Center, Randomized, Parallel Group, Double Blind and Placebo-controlled Clinical Trial to Assess Safety and Tolerability a … Recruiting
  2024-518563-35-00 4 2025-08-25 Alzheimer's Disease
• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting
  2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
• A Phase 3, prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center study of rotigotine in com … Recruiting
  2023-504602-11-00 5 2023-10-25 Mild to moderate Alzheimer's disease
• RCT of Medical Cannabis Aerosol for DPNP Treatment Ended recruitment
  2023-508932-68-00 4 2024-11-14 Diabetic Peripheral Neuropathic Pain
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil … Ended recruitment
  2023-506029-12-00 5 2024-04-03 Migraine
• A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Ended
  2023-506127-29-00 4 2024-03-05 Diabetic Peripheral Neuropathy
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended
  2023-507096-21-00 5 2021-08-16 Chronic or Episodic Migraine (Migraine without aura, migraine with aur
• A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended
  2024-512123-37-00 5 2021-05-27 Parkinson's disease
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended
  2023-506918-45-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4). Ended
  2024-515858-25-00 4 2020-09-30 Subjects with a clinical diagnosis of Alzheimer's disease who are APOE
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• CHRONDI Ended
  2024-513595-17-00 4 CHRONIC PAIN DUE TO DIABETIC PERIPHERAL NEUROPATHY

Showing 1–24 of 24 trials